自引率: 暂无数据
被引量: 0
通过率: 暂无数据
审稿周期: 1
版面费用: 暂无数据
国人发稿量: 12
投稿须知/期刊简介:
Cancer is a devastating disease that causes one in six deaths globally. A large proportion of these deaths could be prevented, but improving prevention and treatment outcomes requires accurate diagnosis, the development of effective and precise treatment modalities and a better understanding of the socioeconomic factors that affect cancer incidence, prevalence and mortality. Nature Cancer aims to provide a unique forum through which the cancer community will learn about the latest, most significant cancer-related advances across the life, physical, applied and social sciences. Areas of interest include fundamental, preclinical research that furthers our understanding of the mechanisms underlying tumour initiation, propagation and progression; work aiming to translate this knowledge to the clinic by focusing on new approaches for the development and delivery of diagnostic and therapeutic modalities; clinical studies informing cancer diagnosis, treatment and prevention; and new ways of understanding the global societal impact of cancer. In addition to publishing original research, Nature Cancer will publish Comments, Reviews, News & Views, Features and Correspondence of high significance across the range of disciplines relating to cancer research. Topics covered in the journal include: • Cancer biology, encompassing oncogenic and tumour-suppressive mechanisms that deregulate molecular pathways and cellular processes, including tumour-initiating cells/cancer stem cells • Cancer genetics and genomics, including functional genomics and the mechanisms underlying genome integrity, genomic instability and mutation • Tumour evolution and heterogeneity • Tumour–host interactions, including the tumour microenvironment (molecular, cellular, physical) and systemic effects • Tumour immunology and immunotherapy • Metastasis, including mechanisms of cancer cell dissemination, seeding, dormancy and growth in secondary sites • Therapy, including design and delivery, targeted, combination and precision therapy and the study of therapy resistance • Clinical work that informs cancer diagnosis, treatment and prevention • Cancer models and methodology to investigate, diagnose and treat cancer • Systems biology, including large-scale and single-cell omics and multi-omics approaches to characterise and study cancer • Social, ethical and policy issues relating to cancer research, prevention, diagnosis and treatment
-
Leveraging the potential for deintensification in cancer care.
被引量：- 发表：1970
-
Deciphering the response to BCMA CAR T cell therapy.
被引量：- 发表：2024
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.
被引量：- 发表：1970
-
Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
Programmed death 1 blockade (tislelizumab) has been approved for metastatic urothelial carcinoma but not as part of neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). In this multicenter single-arm trial (ChiCTR2000037670), 65 participants with cT2-4aN0M0 MIBC received neoadjuvant gemcitabine-cisplatin plus tislelizumab; 57 of them underwent radical cystectomy (RC). The primary endpoint of pathologic complete response (pCR) rate was 50.9% (29/57, 95% confidence interval (CI) 37.3-64.4%) and the pathologic downstaging (secondary endpoint) rate was 75.4% (43/57, 95% CI 62.2-85.9%) in participants undergoing RC. Genomic and transcriptomic analyses revealed three MIBC molecular subtypes (S): S1 (immune-desert) with activated cell-cycle pathway, S2 (immune-excluded) with activated transforming growth factor-β pathway and S3 (immune-inflamed) with upregulated interferon-α and interferon-γ response. Post hoc analysis showed pCR rates of 16% (3/19, S1), 77% (10/13, S2) and 80% (12/15, S3) (P = 0.006). In conclusion, neoadjuvant gemcitabine-cisplatin plus tislelizumab for MIBC was compatible with an enhanced pCR rate.
被引量：- 发表：1970
-
A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies.
The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) are foundational resources in cancer research, providing extensive molecular and phenotypic data. However, large-scale proteomic data across various cancer types for these cohorts remain limited. Here, we expand upon our previous work to generate high-quality protein expression data for approximately 8,000 TCGA patient samples and around 900 CCLE cell line samples, covering 447 clinically relevant proteins, using reverse-phase protein arrays. These protein expression profiles offer profound insights into intertumor heterogeneity and cancer dependency and serve as sensitive functional readouts for somatic alterations. We develop a systematic protein-centered strategy for identifying synthetic lethality pairs and experimentally validate an interaction between protein kinase A subunit α and epidermal growth factor receptor. We also identify metastasis-related protein markers with clinical relevance. This dataset represents a valuable resource for advancing our understanding of cancer mechanisms, discovering protein biomarkers and developing innovative therapeutic strategies.
被引量：- 发表：1970
